🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are on the rise around the world, with data suggesting over 82 million instances each year. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, the spread of superbugs and the very limited treatment choices currently available.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Clearance

Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists hope that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in the same week. This drug, which is employed against urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This approval marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

As per data published in a major medical journal, the new drug eradicated the vast majority of uncomplicated infections. This establishes an equal footing with the current standard treatment, which uses two antibiotics. The study enrolled over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in a wide range of regions with limited resources.

Doctors on the front lines have expressed hope. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for managing the epidemic. This is viewed as essential to lessen the impact of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.